顧糖維膜衣錠 1000 毫克

Nchi: Taiwani

Lugha: Kichina

Chanzo: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Viambatanisho vya kazi:

METFORMIN

Inapatikana kutoka:

台灣默克股份有限公司 台北市內湖區堤頂大道2段89號6樓 (23526610)

ATC kanuni:

A10BA02

Dawa fomu:

膜衣錠

Tungo:

METFORMIN (6820400700) (equivalent to metformin base)(780mg)MG

Vitengo katika mfuko:

塑膠瓶裝;;鋁箔盒裝

Darasa:

製　劑

Dawa ya aina:

須由醫師處方使用

Viwandani na:

MERCK SANTE S.A.S. – CENTRE DE MEYZIEU 10 AVENUE DE LATTRE DE TASSIGNY 69330 MEYZIEU – FRANCE FR

Eneo la matibabu:

metformin

Matibabu dalili:

「成人及12歲(含)以上的兒童或青少年之第二型糖尿病患者。」說明：飲食控制及運動皆無法達到理想的血糖控制下，可選擇Glucophage作為其輔助療法。

Bidhaa muhtasari:

註銷日期: 2017/04/12; 註銷理由: 自請註銷; 有效日期: 2017/07/06; 英文品名: Glucophage Film-coated tablets 1000mg

Idhini hali ya:

已註銷

Idhini ya tarehe:

2012-07-06

Taarifa za kipeperushi

FILM-COATED TABLETS
METFORMINHYDROCHLORIDE
COMPOSITION

Each film-coated tablet of Glucophage 500 mg contains as active
ingredient 500 mg metformin hydrochloride (equivalent to 390 mg
metformin base).

Each film-coated tablet of Glucophage 850 mg contains as active
ingredient 850 mg metformin hydrochloride (equivalent to 663 mg
metformin base)

Each film-coated tablet of Glucophage 1000 mg contains as active
ingredient 1000 mg metformin hydrochloride (equivalent to 780 mg
metformin base).
Excipients:

Povidone K30, magnesium stearate and hypromellose

Povidone K30, magnesium stearate, hypromellose, macrogol 400 and
macrogol 8000
PROPERTIES
PHARMACODYNAMICS
Glucophage is an antidiabetic medicine that belongs to the group of
biguanides. Metformin, the active ingredient in Glucophage, reduces
hepatic glucose production, increases insulin sensitivity in muscles
and
delays intestinal glucose absorption.
A reduction of diabetic complications has been shown in overweight
type
2 diabetic adult patients treated with Glucophage as first-line
therapy
after diet therapy. Glucophage is associated with either a stable body
weight or modest weight loss.
PHARMACOKINETICS
Absorption:
After an oral dose of metformin hydrochloride tablet, maximum plasma
concentration (C
max
) is reached in approximately 2.5 hours (t
max
). Absolute
bioavailability of a 500 mg or 850 mg metformin hydrochloride tablet
is approximately 50-60% in healthy subjects. After an oral dose, the
non-absorbed fraction recovered in faeces was 20-30%.
After oral administration, metformin absorption is saturable and
incomplete. It is assumed that the pharmacokinetics of metformin
absorption is non-linear.
At the recommended metformin doses and dosing schedules, steady
state plasma concentrations are reached within 24 to 48 hours and are
generally less than 1 microgram/ml. In controlled clinical trials,
maximum
metformin plasma levels (C
max
) did no